PVALB and psychotic disorder: A leading contemporary preclinical model of psychosis proposes that these symptoms arise from a substantial decrease in the number of inhibitory parvalbumin-expressing GABAergic interneurons in the hippocampus, resulting in an overactive striatal dopamine system through manipulation of glutamatergic pyramidal neurons (Lodge and Grace, 2011; Grace, 2016).